Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Liabilities and Shareholders Equity (2023 - 2025)

Historic Liabilities and Shareholders Equity for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $252.4 million.

  • Tonix Pharmaceuticals Holding's Liabilities and Shareholders Equity rose 16575.71% to $252.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $795.6 million, marking a year-over-year increase of 7481.12%. This contributed to the annual value of $162.9 million for FY2024, which is 545.98% up from last year.
  • Latest data reveals that Tonix Pharmaceuticals Holding reported Liabilities and Shareholders Equity of $252.4 million as of Q3 2025, which was up 16575.71% from $187.4 million recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Liabilities and Shareholders Equity registered a high of $252.4 million during Q3 2025, and its lowest value of $70.3 million during Q2 2024.
  • For the 3-year period, Tonix Pharmaceuticals Holding's Liabilities and Shareholders Equity averaged around $157.2 million, with its median value being $159.7 million (2023).
  • As far as peak fluctuations go, Tonix Pharmaceuticals Holding's Liabilities and Shareholders Equity tumbled by 5598.55% in 2024, and later skyrocketed by 16648.7% in 2025.
  • Quarter analysis of 3 years shows Tonix Pharmaceuticals Holding's Liabilities and Shareholders Equity stood at $154.5 million in 2023, then rose by 5.46% to $162.9 million in 2024, then soared by 54.98% to $252.4 million in 2025.
  • Its Liabilities and Shareholders Equity was $252.4 million in Q3 2025, compared to $187.4 million in Q2 2025 and $192.9 million in Q1 2025.